Teneliximab

Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40. As of 2009, it has not entered clinical trials.[2]

Teneliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetCD40
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 NY (what is this?)  (verify)

References
  1. International Nonproprietary Names For Pharmaceutical Substances
  2. Iqbal S. Grewal, ed. (January 15, 2009). Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology). Springer. p. 22. ISBN 0-387-89519-1.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.